MGH to study Philips' digital pathology tools to get diagnostic clearance

Royal Philips ($PHG) announced Massachusetts General Hospital will study the reproducibility of its digital pathology whole slide imaging (WSI) IntelliSite Solution to get to clearance to use the device for primary diagnostic use. "With rising health care costs, we have a public responsibility to work effectively," said study principal investigator Dr. Jochen Lennerz. "Through the genomic revolution we have started to learn how to manage big data. Now there is a pressing need to gain access to and increase flexibility in how pathologists manage the massive amounts of imaging data we procure every day." More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.